Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Mitoxantrone × Head & Neck × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 147 Lymphoid 73 Genitourinary 28 Myeloid 19 Breast 7 Classical hematology 6 Sarcoma 4 Gynecologic 4 Tumor-Agnostic 2 Plasma cell 2 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Cisplatin 541 pembrolizumab 283 Radiotherapy 279 Cetuximab 235 Docetaxel 196 Radiotherapy, Intensity-Modulated 186 Fluorouracil 174 Carboplatin 173 Paclitaxel 146 Nivolumab 120 Gemcitabine 112 Radiation 76 Magnetic Resonance Spectroscopy 76 toripalimab 68 Drug Therapy 68 Capecitabine 67 durvalumab 54 Surgical Procedures, Operative 53 Biopsy 48 Cyclophosphamide 43 camrelizumab 41 Standard of Care 39 Chemoradiotherapy 39 Specimen Handling 38 Erlotinib Hydrochloride 38 Bevacizumab 38 tislelizumab 37 130-nm albumin-bound paclitaxel 36 Radiosurgery 35 atezolizumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡